An early-stage biotech company based in Natick, MAandhaving alimited SBIR presence, VirTech Bio has developed a novel, proprietary hemoglobin-based oxygen carrier (HBOC) solution - OxyBridge - for use both in vivo and ex vivo applications: a proprietary HBOC solution for in vivo applications like severe blood loss and such ex vivo applications as supporting organs prior to transplant. Though not recently SBIR involved. the firm's team of scientists, engineers and industry veterans are committed to delivering a universal HBOC solution to fulfill significant unmet medical needs and save lives when minutes matter that deserves acknowldgement with their efforts worthy of note. Specifically, the firm is organzied around the critical task of transforming current organ transplant science, technologies and techniques to provide more reliable, effective and life saving solutions for humanity. With hemorrhage being the leading cause of trauma-related death in both civilian and military populations, as a firm Virtech Bio Inc is focused on reshaping the modern blood replacement system. With the firm's lead product called OxyBridge - Supercharged oxygen delivery, Human-derived, hemoglobin-based - principals of the firm have developed a room-temperature stable, ready-to-use oxygen-carrying plasma expander to restore circulatory system parameters in pre-hospital settings. The firm is developing innovative therapies for organ and tissue preservation, ex vivo organ management and biomarker discovery using a technology platform combining machine perfusion (MP) with a new hemoglobin-based oxygen carrier (HBOC). With current transplant protocols sometimes leading to damaged organs and suboptimal outcomes, VirTech has developed a novel approach for oxygen delivery while managing organs and tissue outside the body improving organ quality and extends viability
